RCM
PGNX

Riverhead Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Riverhead Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-12,563
Closed -$79K – 1587
2018
Q3 		$79K Buy
12,563
+900
+8% +$6.91K ﹤0.01% 1436
2018
Q2 		$94K Hold
11,663
– – ﹤0.01% 1357
2018
Q1 		$87K Buy
11,663
+2,700
+30% +$18K ﹤0.01% 1377
2017
Q4 		$53K Buy
8,963
+2,200
+33% +$13.4K ﹤0.01% 1468
2017
Q3 		$50K Buy
6,763
+1,640
+32% +$10.4K ﹤0.01% 1446
2017
Q2 		$35K Buy
5,123
+2,723
+113% +$20.1K ﹤0.01% 1471
2017
Q1 		$23K Buy
+2,400
New +$24K ﹤0.01% 1448

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Riverhead Capital Management's PGNX Position: Q4 2018 in Review

Riverhead Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2018, closing a stake of 12,563 shares — an estimated $79K sold.

Riverhead Capital Management first reported a position in PGNX in Q1 2017 and held it in 7 quarters. The position peaked at $94K in Q2 2018. 150 funds tracked by Wall St. Rank hold PGNX as of Q4 2018.

  • Riverhead Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • Riverhead Capital Management sold 12,563 Progenics Pharmaceuticals Inc shares in Q4 2018, an estimated $79K.
  • Riverhead Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 7 quarters.
  • Riverhead Capital Management's Progenics Pharmaceuticals Inc position peaked at $94K in Q2 2018.
  • 150 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2018.

Based on Riverhead Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.